In two multicentre Phase I/II trials conducted by Drilon [29]and Griesinger [19], 69 previously untreated patients with RET fusion-positive NSCLC who received Selpercatinib had an ORR of 84% and mPFS of 22.0 months. Here, RET is linked to non-small cell lung carcinoma.